Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies—pharmacovigilance database analysis with real-world data validation

Fig. 3

Relative risk of interstitial pneumonitis under different ICI drugs in non-small cell lung cancer patients. Each cell contains the adjusted ROR and its 95% confidence interval of IP under treatment in the rows using that in the column as a reference. All of the number in bold were statistically significant. Since only one case received IPIL combined with RT and no case received AVEL combined with RT, these regimens were not invested further. The P-value for adjusted ROR was calculated using a multivariable logistic regression model and was adjusted by using the “p.adjusted()” command in R. Abbreviations: ROR, reporting odds ratio; RT, radiation therapy; ICI, immune checkpoint inhibitor therapy; NIVO, nivolumab; PEMB, pembrolizumab; DURV, durvalumab; ATEZ, atezolizumab; AVEL, avelumab; IPIL, ipilimumab

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us